Immatics NV (Immatics NV) Float Percentage Of Total Shares Outstanding : 79.08% (As of May. 06, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immatics NV's float shares is 81.44 Mil. Immatics NV's total shares outstanding is 102.99 Mil. Immatics NV's float percentage of total shares outstanding is 79.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immatics NV's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immatics NV's Institutional Ownership is 17.42%.

Immatics NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Immatics NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	81.44	/	102.99
	=	79.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immatics NV (Immatics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

4A3:Germany

Address

Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.